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Use of Management Pathways or Algorithms
in Children With Chronic Cough
CHEST Guideline and Expert Panel Report
Anne B. Chang, MBBS, PhD, MPH; John J. Oppenheimer, MD; Miles M. Weinberger, MD, FCCP; Bruce K. Rubin, MD;
Kelly Weir, BSpThy, MSpPath, PhD, CPSP; Cameron C. Grant, MBChB, PhD; Richard S. Irwin, MD, Master FCCP; on behalf
of the CHEST Expert Cough Panel
BACKGROUND: Using management algorithms or pathways potentially improves clinical out-
comes.We undertook systematic reviews to examine various aspects in the generic approach (use
of cough algorithms and tests) to themanagement of chronic cough in children (aged# 14 years)
based on key questions (KQs) using the Population, Intervention, Comparison,Outcome format.
METHODS: We used the CHEST Expert Cough Panel’s protocol for the systematic reviews and
the American College of Chest Physicians (CHEST) methodological guidelines and Grading of
Recommendations Assessment, Development and Evaluation framework. Data from the sys-
tematic reviews in conjunction with patients’ values and preferences and the clinical context
were used to form recommendations. Delphi methodology was used to obtain the ﬁnal grading.
RESULTS: Combining data from systematic reviews addressing ﬁve KQs, we found high-
quality evidence that a systematic approach to the management of chronic cough
improves clinical outcomes. Although there was evidence from several pathways, the highest
evidence was from the use of the CHEST approach. However, there was no or little evidence
to address some of the KQs posed.
CONCLUSIONS: Compared with the 2006 Cough Guidelines, there is now high-quality
evidence that in children aged # 14 years with chronic cough (> 4 weeks’ duration), the
use of cough management protocols (or algorithms) improves clinical outcomes, and cough
management or testing algorithms should differ depending on the associated characteristics
of the cough and clinical history. A chest radiograph and, when age appropriate, spirometry
(pre- and post-b2 agonist) should be undertaken. Other tests should not be routinely per-
formed and undertaken in accordance with the clinical setting and the child’s clinical
symptoms and signs (eg, tests for tuberculosis when the child has been exposed).
CHEST 2017; 151(4):875-883
KEY WORDS: cough; evidence-based medicine; guidelines; pediatrics
ABBREVIATIONS: ACCP = American College of Chest Physicians;
AHR = airway hyperresponsiveness; KQ = key question; LR = likeli-
hood ratio; PC-QOL = Parent Cough-Speciﬁc Quality of Life;
PedsQL = Pediatric Quality of Life Inventory; PICO = Population,
Intervention, Comparison, Outcome; PV = predictive value; QoL =
quality of life; RCT = randomized controlled trial
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Commonwealth University (Dr Rubin), Richmond, VA; Department of
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and Health Sciences, The University of Auckland, Auckland, New
Zealand; and Pediatric Allergy, Immunology, and Pulmonology Divi-
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DISCLAIMER: American College of Chest Physician guidelines are
intended for general information only, are not medical advice, and do
not replace professional medical care and physician advice, which
always should be sought for any medical condition. The complete
disclaimer for this guideline can be accessed at http://www.chestnet.
org/Guidelines-and-Resources/Guidelines-and-Consensus-Statements/
CHEST-Guidelines.
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Summary of Recommendations/Suggestions
1. For children aged £ 14 years, we suggest deﬁning
chronic cough as the presence of daily cough of at least
4 weeks in duration (Ungraded, Consensus Based
Statement).
2. For children aged £ 14 years with chronic cough, we
suggest that an assessment of the effect of cough on
the child and the family be undertaken as part of the
clinical consultation (Ungraded, Consensus Based
Statement).
3. For children aged £ 14 years with chronic cough, we
recommend using pediatric-speciﬁc cough
management protocols or algorithms (Grade 1B).
4. For children aged £ 14 years with chronic cough, we
recommend taking a systematic approach (such as
using a validated guideline) to determine the cause of
the cough (Grade 1A).
5. For children aged £ 14 years with chronic cough,
we recommend basing the management or testing
algorithm on cough characteristics and the
associated clinical history, such as using speciﬁc
cough pointers like presence of productive/wet
cough (Grade 1A).
6. For children aged £ 14 years with chronic cough, we
recommend basing the management on the etiology of
the cough. An empirical approach aimed at treating
upper airway cough syndrome due to a rhinosinus
condition, gastroesophageal reﬂux disease, and/or
asthma should not be used unless other features
consistent with these conditions are present
(Grade 1A).
7. For children aged £ 14 years with chronic cough, we
suggest that if an empirical trial is used based on
features consistent with a hypothesized diagnosis, the
trial should be of a deﬁned limited duration in order
to conﬁrm or refute the hypothesized diagnosis
(Ungraded, Consensus Based Statement).
8. For children aged £ 14 years with chronic cough, we
recommend that a chest radiograph and, when age
appropriate, spirometry (pre- and post-b2 agonist) be
undertaken (Grade 1B).
9. For children aged £ 14 years with chronic cough, we
suggest undertaking tests evaluating recent Bordetella
pertussis infection when pertussis is clinically
suspected (Ungraded, Consensus Based Statement).
10. For children aged £ 14 years with chronic cough,
we recommend not routinely performing additional
tests (eg, skin prick test, Mantoux, bronchoscopy,
chest CT); these should be individualized and
undertaken in accordance with the clinical setting and
the child’s clinical symptoms and signs (Grade 1B).
11. For children aged > 6 years and £ 14 years with
chronic cough and asthma clinically suspected, we
suggest that a test for airway hyperresponsiveness
(AHR) be considered (Grade 2C).
Chronic cough among children is associated with
impaired quality of life,1 multiple physician visits,2 and
adverse effects from inappropriate use of medications.3
Also, it may signify a serious underlying disease such
as bronchiectasis or an inhaled foreign body.1 Further,
early diagnosis is important, as delayed diagnosis
(eg, foreign body) may cause chronic respiratory
morbidity,4 whereas early diagnosis of chronic disease
leads to appropriate management and subsequent
resolution of cough and improved quality of life (QoL).1
Use of cough algorithms or pathways can potentially
lead to earlier diagnosis and reduce morbidity,
unnecessary costs, and medication use associated with
chronic cough.
In the management of chronic cough (ie, cough of more
than 4 weeks’ duration), investigations are undertaken
to conﬁrm or rule out speciﬁc causes. When undertaking
investigations in children, the pediatric-speciﬁc
issues and risk-beneﬁt ratio needs to be taken into
consideration. For example, although respiratory
function tests are standard assessments in adults, most
young children are unable to generate reliable data from
pulmonary function tests (such as spirometry and AHR
challenges) until the age of 6 years in most clinical
laboratories. Chest CT scans are associated with higher
adverse events in young children (future cancer)5 and
may require a general anesthetic in children
aged < 3 years.
The 2006 American College of Chest Physicians
(CHEST) guidelines on chronic cough in children6
advocated use of a cough pathway based on available but
FUNDING/SUPPORT: The authors have reported to CHEST that no
funding was received for this study.
CORRESPONDENCETO: Anne B. Chang,MBBS, PhD,MPH,Department
of Respiratory and Sleep Medicine, Lady Cilento Children’s Hospital,
South Brisbane, QLD 4101, Australia; e-mail: annechang@ausdoctors.net
Copyright  2017 American College of Chest Physicians. Published by
Elsevier Inc. All rights reserved.
DOI: http://dx.doi.org/10.1016/j.chest.2016.12.025
876 Evidence-Based Medicine [ 1 5 1 # 4 CHES T A P R I L 2 0 1 7 ]
limited evidence in that era. Research in chronic cough
has progressed in the past decade, and hence we
undertook systematic reviews addressing key questions
(KQs) using the Population, Intervention, Comparison,
Outcome (PICO) format relating to various aspects
of cough algorithms/pathways7 and routine tests
(e-Appendix 1). The 5 KQs were the following:
 KQ1: In children aged # 14 years with chronic cough
(> 4 weeks’ duration), does the use of cough man-
agement protocols (or algorithms) improve clinical
outcomes?
 KQ2: In children aged # 14 years with chronic cough
(> 4 weeks’ duration), should the cough or testing
algorithm differ depending on the duration and/or
severity?
 KQ3: In children aged # 14 years with chronic cough
(> 4 weeks’ duration), should the cough or testing
algorithm differ depending on the associated charac-
teristics of the cough and clinical history?
 KQ4: In children aged # 14 years, what testing or tests
should be routinely done in clinical practice when
evaluating chronic cough of at least 4 weeks’ duration?
 KQ5: When evaluating children aged # 14 years with
chronic cough (of at least 4 weeks’ duration), what is
the role of pulmonary function studies and bronchial
provocation in clinical practice?
In this paper, our overall aim was to present the
recommendations and the summary of evidence behind
these recommendations relating to the assessment and
use of management pathways or algorithms in children
with chronic cough. Systematic reviews addressing PICO-
formatted KQs relating to various aspects of cough
algorithms were undertaken and previously published in
part and are best read together with this document.7
Methods
For the CHEST cough guidelines, it was a priori determined that the
age cutoff for pediatric and adult components was 14 years. We used
a standard method8 as previously described by Vertigan, et al9: “The
methodology used by the CHEST Guideline Oversight Committee to
select the Expert Cough Panel Chair and the international panel of
experts, perform the synthesis of the evidence and develop the
recommendations and suggestions has been published.8,10 Key
questions and parameters of eligibility were developed for this topic.
Existing guidelines, systematic reviews, and primary studies were
assessed for relevance and quality, and were used to support the
evidence-based graded recommendations or suggestions. A highly
structured consensus-based Delphi approach was employed to
provide expert advice on all guidance statements. The total number
of eligible voters for each guideline statement varied based on the
number of managed individuals recused from voting on any
particular statements because of their potential conﬂicts of interest.
Transparency of process was documented. Further details of the
methods have been published elsewhere.8,10 Consistent with recent
recommendations from the Institute of Medicine, the Panel
conducted a comprehensive, systematic review of the literature to
provide the evidence base for this guideline.”
Guideline Framework
As previously described,9 “the ACCP has adopted the GRADE
framework (The Grading of Recommendations Assessment,
Development and Evaluation). This framework separates the process
of rating the quality of evidence from that of determining the
strength of recommendation. The quality of evidence is based on the
ﬁve domains of risk of bias, inconsistency, indirectness, reporting
bias and imprecision. The quality of evidence (ie, the conﬁdence in
estimates) is rated as high (A), moderate (B), low or very low (C).
The strength of recommendation is determined based on the quality
of evidence, balance of beneﬁts and harms, patients’ values and
preferences, and availability of resources. Recommendations can be
strong or weak.”
State of the Available Evidence
Searches for the systematic reviews were undertaken externally by
librarians (Nancy Harger, MLS and Judy Nordberg, MLS) from
the University of Massachusetts Medical School, Worcester, MA.
These searches were undertaken between February 28, 2015 and
August 14, 2015 using an a priori established protocol for each
KQ.7 The evidence for three KQs was summarized in a previous
publication7 (and key tables and ﬁgures in e-Appendix 1, e-Tables
1-3, and e-Figs 1-3) and reproduced in e-Appendix 1, e-Tables 4
and 5, and e-Figures 4 and 5 along with the data relevant for KQs
4 and 5.
The systematic reviews7 (and e-Appendix 1, e-Tables 4 and 5, e-Figs 4
and 5) identiﬁed high-quality evidence to support some
recommendations but not all. When there was insufﬁcient evidence
for diagnosis and management recommendations, the panel heavily
placed great emphasis on patient values, preferences, ease and cost of
tests, and availability of potential therapies. The panel also made
several suggestions for future research.
Results
The ﬁrst eight recommendations and/or suggestions were
derived from systematic reviews that addressedKQs 1 to 3
summarized in e-Tables 1-3 and e-Figures 1-3.7 The
subsequent four recommendations/suggestions were
derived from systematic reviews that addressedKQs 4 and
5 (all summarized in e-Tables 4 and 5 and e-Figs 4 and 5).
Summary of Evidence and Interpretation
The deﬁnition of the duration of chronic cough is
controversial, because in a minority of children, cough
after viral infections lasts > 4 weeks. In our systematic
review,7 (e-Tables 1 and 2), we found no studies that
addressed the question ofwhether the coughmanagement
or testing algorithm should differ depending on the
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duration of chronic cough (KQ 2). Also to date, there are
no published studies that have clinically assessed the
possible reasons and/or outcomes of the group of children
with acute cough that persists for > 4 weeks.
In reviewing published national guidelines, we found
that all but one11 guideline deﬁned chronic cough in
children as a duration lasting > 4 weeks (e-Table 2). All
the guidelines (such as those of ACCP,6 and the
Thoracic Society of Australia and New Zealand12) that
use the shorter time frame do not advocate the use of
medications or investigations for all children at that time
point, recognizing that the cough subsides without any
speciﬁc treatment in a number of children (ie, assumed
“resolved spontaneously”).1,13 The shorter time frame is
recommended for reasons outlined in previous
publications.1,12 One such reason is to ensure that all
children with chronic cough are carefully assessed and
not quickly dismissed as having a postviral cough. This
is particularly important in children, as chronic cough
may be due to a serious underlying condition, and
earlier diagnosis and treatment results in less damage
(eg, retained foreign body4 and bronchiectasis14).
Indeed, a serious potentially progressive underlying
respiratory illness (bronchiectasis, aspiration lung
disease, or cystic ﬁbrosis) was documented in 18% of
children in a multicenter study that used a cough
algorithm.1 Thus, for safety reasons, we advocated that
chronic cough should be deﬁned as that lasting
> 4 weeks.
1. For children aged £ 14 years, we suggest deﬁning
chronic cough as the presence of daily cough of at least
4 weeks in duration (Ungraded, Consensus Based
Statement).
Summary of Evidence and Interpretation
Our systematic review7 found no eligible studies that
examined whether the cough testing algorithm should
differ depending on the severity of the cough
(e-Table 2). Almost all existing nationally based cough
guidelines suggest that cough severity should be
assessed, along with burden and expectations. However,
these recommendations are generic, with little detail
regarding how to assess cough severity.
Although cough is often dismissed by health
professionals as a minimal ailment, cough causes
substantial burden. In a prospective multicenter cohort
study1 involving 346 children who ﬁrst presented to
pediatric pulmonologists with a chronic cough, the
burden of chronic cough (measured by a generic
health-related QoL [Pediatric Quality of Life Inventory
{PedsQL}15] and a cough-speciﬁc QoL [Parent Cough-
Speciﬁc Quality of Life {PC-QOL}16,17]) differed
signiﬁcantly between clinical settings but was not
inﬂuenced by age or cause of cough. Also, duration of
cough and cough score were no different in children
with a serious underlying disease compared with those
with less serious conditions.1 This suggests that it is the
cough itself, rather than the underlying cause, that drives
the disease burden at the point of referral. Further, the
cohort’s1 mean normalized PedsQL score of 74.7 was in
the realm of children with other chronic illnesses
(cardiac, 79.4; diabetes, 76.6; obesity, 75; and
gastrointestinal conditions, 72.4).18
2. For children aged £ 14 years with chronic cough, we
suggest that an assessment of the effect of cough on
the child and the family be undertaken as part of the
clinical consultation (Ungraded, Consensus Based
Statement).
Summary of Evidence and Interpretation
Our systematic review7 found high-quality evidence
that in children aged # 14 years with chronic cough
(> 4 weeks’ duration), the use of children-speciﬁc cough
management protocols (or algorithms) improves clinical
outcomes (e-Table 1). When data were available,
ﬁndings from randomized controlled trials (RCTs) were
consistent with those derived from cohort studies.7 All
studies within the past decade used systematic
evaluation of the child.
The highest evidence for the type of chronic cough
pathway was that derived from the American College of
Chest Physicians,6 as the evidence was derived from
an RCT19 and several cohort studies.20-22 The evidence
for other pathways was restricted to single studies
(e-Table 1). The variations in algorithms raise the
question of whether algorithms that are speciﬁc to the
clinical setting should be used, such as in developing
countries, where the most common causes of cough are
likely different (eg, tuberculosis, parasitic disease).
However, irrespective of the relative prevalence of
different conditions, the correct diagnosis would be
obtained if a cough pathway such as the CHEST
guideline is used.
3. For children aged £ 14 years with chronic cough, we
recommend using pediatric-speciﬁc cough
management protocols or algorithms (Grade 1B).
4. For children aged £ 14 years with chronic cough, we
recommend taking a systematic approach (such as
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using a validated guideline) to determine the cause of
the cough (Grade 1A).
Summary of Evidence and Interpretation
Our systematic reviews7 also found high-quality evidence
that in children (aged#14 years) with chronic cough, the
cough management or testing algorithm should differ
depending on the associated characteristics of the cough
and clinical history (e-Tables 3a, 3b). We7 found that all
included studies demonstrated that cough management
should differ depending on clinical history, including
cough characteristics. None of the studies used an
empirical approach. At a divergent point, all studies used
the concept of wet or productive cough, but the point of
when this divergence occurred differed between the
algorithms.7 A study that speciﬁcally examined the use of
cough pointers22 found that the presence of any speciﬁc
cough pointer indicating a cause of chronic cough (as
opposed to resolution without speciﬁc treatment) had
sensitivity of 1.0 (95% CI, 0.98-1.0), speciﬁcity of 0.95
(95% CI, 0.82-0.99), positive predictive value (PV) of 0.99
(95% CI, 0.97-1.0), negative PV of 1.0 (95% CI, 0.9-1.0),
positive likelihood ratio (LR) of 20 (95%CI, 5.2-77.2), and
negative LRof 0 (95%CI, 0-0.03).However, recognition of
cough pointers (Table 1)23 is dependent on accurate
identiﬁcation (ie, expertise of physicians and the
caregiver’s history).
Our systematic review7 also found that the majority of
children in all the studies received treatment speciﬁc for
the underlying cause rather than an empirical approach
based on treatment of gastroesophageal reﬂux disease,
upper airway cough syndrome due to a rhinosinus
condition, or asthma (e-Table 3). However, in some
situations, an empirical trial is required, such as using
inhaled corticosteroids when the cough is dry and
objective testing cannot be undertaken in a young child.
Ascribing causes for the cough has an inherent high risk
of bias related to the placebo and “period effects” (the
natural resolution of cough over time24) evident in
cough-related intervention studies.25 These risks of bias
can be reduced by limiting the time frame in which
“response to treatment” is considered,25 when an RCT is
not undertaken.
5. For children aged £ 14 years with chronic cough, we
recommend basing the management or testing
algorithm on cough characteristics and the associated
clinical history, such as using speciﬁc cough pointers
like presence of productive/wet cough (Grade 1A).
6. For children aged £ 14 years with chronic cough,
we recommend basing the management on the
etiology of the cough. An empirical approach aimed
at treating upper airways cough syndrome due to a
rhinosinus condition, gastroesophageal reﬂux disease,
and/or asthma should not be used unless other
features consistent with these conditions are present
(Grade 1A).
7. For children aged £ 14 years with chronic cough, we
suggest that if an empirical trial is used based on
features consistent with a hypothesized diagnosis, the
TABLE 1 ] Extended List of Cough Pointers (Modiﬁed From Previous Papers)6,12,23
Systemic Pulmonary
 Cardiac abnormalities  Chest pain
 Digital clubbing  Daily moist or productive cough
 Failure to thrive  Hemoptysis
 Medications or drugs associated with chronic cough
(angiotensin-converting enzyme inhibitors, illicit drug
use)
 Abnormal cough characteristics (brassy, plastic bronchitis,
paroxysmal with/without posttussive vomiting, staccato,
cough from birth)
 Neurodevelopmental abnormality  Recurrent pneumonia
 Fever  Hypoxia/cyanosis
 Immune deﬁciency (primary or secondary)  History of previous lung disease or predisposing causes
(eg, neonatal lung disease, foreign body aspiration)
 Feeding difﬁculties  Exertional dyspnea
 History of contacts (eg, tuberculosis)  Dyspnea at rest or tachypnea
 Chest wall deformity
 Auscultatory ﬁndings (eg, stridor, wheeze, crackles)
 Chest radiograph abnormalities
 Pulmonary function test abnormalities
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trial should be of a deﬁned limited duration in order
to conﬁrm or refute the hypothesized diagnosis
(Ungraded, Consensus Based Statement).
Summary of Evidence and Interpretation
Of the studies included in our systematic reviews,7 less
than one-half of the studies a priori deﬁned how cough
was measured and what constituted cough resolution
and/or considered the period effect (e-Tables 1 and 3).
Many also lacked standardization of deﬁning cough
outcomes. Thus, further high-quality studies using
validated tools,26 particularly in primary care settings,
are needed. This includes use of methods that take into
account the period effect and use of a priori deﬁnitions
for cause and response using validated pediatric-speciﬁc
cough outcome measures such as the PC-QOL.16,27
Several but not all guidelines recommend that chest
radiographs and spirometry be undertaken in all
children presenting with chronic cough (Table 2).28-32 In
KQ4, our systematic review examined whether any
routine investigations should be undertaken in all
children with chronic cough, and in KQ5, we evaluated
speciﬁc cohorts that related to more complex lung
function tests.
For KQ4 (e-Fig 4, e-Table 4), we identiﬁed one RCT,19
undertaken in pediatric pulmonology clinics, in which
management was based on identiﬁcation of cough
pointers (Table 1) that included abnormalities detected
on the chest radiograph and spirometry. The rest of
the included studies were lower-quality studies; two
were retrospective studies33,34 and nine were
prospective studies.20-22,35-40 One of the prospective
studies41 included children in the RCT19 that
calculated the LRs of the utility of spirometry and
chest radiograph. For both tests, the positive LRs were
inﬁnite, but negative LRs were not highly negative,
indicating that both tests are good for ruling in disease
when abnormalities are present but poor at ruling out
disease. For example, abnormal spirometry values at
baseline with bronchodilator reversibility provide
objective evidence consistent with asthma. However,
asthma cannot be ruled out when spirometry values
are normal. Results from these studies indicate that the
risk-beneﬁt ratio of both spirometry and chest
radiograph clearly favors the beneﬁt arm.
Although our search identiﬁed several studies evaluating
the prevalence of recent B pertussis infection in children
with cough, these studies42,43 did not fulﬁll our
systematic review’s inclusion criteria of cough
duration.36,37 Although the studies reported a mean
cough duration of > 4 weeks (range not given), the
inclusion criteria for both studies was > 2 weeks.
Nevertheless, these studies, conducted in primary care,
suggested that appropriate tests to evaluate for recent
pertussis infection should be undertaken when clinically
appropriate. The most appropriate test (culture,
polymerase chain reaction, or serologic analysis) is
dependent on the child’s age and duration of
symptoms.44 The 2006 ACCP guideline6 advocated that
testing for recent B pertussis infection be undertaken
when clinically suspected (eg, contact, posttussive
vomiting, whoop), as described in several studies.19-22,40
TABLE 2 ] Summary of Pediatric Chronic Cough Guidelines on the Use of Routine Tests
Study/Year Country Society Suggested Routine Tests
Chang et al12/2006 Australia Thoracic Society of Australia and
New Zealand
Yes
Spirometrya and chest radiography
Chang and Glomb6/2006 United States American College of Chest
Physicians
Yes
Spirometrya and chest radiography
Gibson et al28/2010 Australia Australian Lung Foundation Yes
Spirometrya and chest radiography
Kohno et al29/2006 Japan Japanese Respiratory Society No
Leconte et al30/2008 Belgium Primary care No
Tests based on clinical suspicion
Lu31/2014 China Multiple societies Yes (based on translated article)
Chest radiography
Shields et al11/2008 England British Thoracic Society Yes
Spirometrya and chest radiography
Zacharasiewicz et al32/2014 Austria Austrian Society of Pediatrics,
Austrian Society Pneumology
Yes
Spirometrya and chest radiography
aSpirometry if age appropriate (usually when aged > 5 years but in some centers, spirometry can be undertaken in children > 3 years).
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Other than chest radiograph and spirometry, few studies
have systematically undertaken tests in the cohorts of
children. Skin prick testing to assess atopy, undertaken
in several studies,33,35,38 was generally not useful in
aiding the diagnosis of chronic cough. This is not
surprising, as although atopy increases the probability of
having asthma, it presence or absence is a poor sole
distinguishing feature for pediatric asthma.45 In a study
involving 202 children, atopy (deﬁned by skin prick
testing) did not inﬂuence cough receptor sensitivity to
capsaicin.46
One study36 undertaken in a setting with a high
prevalence (relative to afﬂuent countries) of tuberculosis
found that sequential testing (including a Mantoux test)
identiﬁed tuberculosis in 22% of the 94 children. This
study36 and other studies19-22,37,39,40 that undertook tests
in accordance with the clinical ﬁndings suggest that
other than chest radiograph and spirometry, other tests
should be targeted. Another such example is provided by
data from an Iranian study47 (excluded because
inclusion criteria was > 2 weeks of cough), that
described a high frequency of Toxocara IgG, peripheral
blood eosinophilia, and hypereosinophilia (14%, 55%,
and 80%, respectively) in children with chronic cough.
8. For children aged £ 14 years with chronic cough, we
recommend that a chest radiograph and, when age
appropriate, spirometry (pre- and post-b2 agonist) be
undertaken (Grade 1B).
9. For children aged £ 14 years with chronic cough, we
suggest undertaking tests evaluating recent Bordetella
pertussis infection when pertussis is clinically
suspected (Ungraded, Consensus Based Statement).
10. For children aged £ 14 years with chronic cough,
we recommend not routinely performing additional
tests (eg, skin prick test, Mantoux, bronchoscopy,
chest CT); these should be individualized and
undertaken in accordance with the clinical setting and
the child’s clinical symptoms and signs (Grade 1B).
Summary of Evidence and Interpretation
Four relevant studies33,35,38,48 were included in the
systematic review for KQ5 (e-Fig 5, e-Table 5).
There were no RCTs. One was a retrospective study
and three were prospective single-center studies that
undertook different types of bronchoprovocation
investigations. The deﬁnition of presence of AHR
varied among the studies. One study38 included
children with wheeze, two33,35 excluded a history of
wheeze, and the remaining study48 did not specify or
mention wheeze in the inclusion or exclusion criteria.
However, one35 of the studies that excluded children
with wheeze included children with exertional dyspnea.
None of the studies were of high quality, but all studies
showed that AHR suggestive of asthma was
demonstrated in a subgroup of children with chronic
cough. Oral theophylline was used in two studies,33,35
and both reported rapid cessation of cough. Some
children in the latter study,33 a retrospective review of
charts, were also treated with an oral or inhaled short-
acting b2 agonist. Thus, there are insufﬁcient data
to recommend that testing for AHR should be
undertaken in all children with chronic cough. When
asthma is suspected and/or other symptoms are
present (eg, history of wheeze, exertional dyspnea,
history of atopy), we suggest that testing for AHR
should be considered (if possible) when the spirometry
values are normal and other concurrent evidence of
asthma is not evident. As it is beyond our scope to
discuss the role of AHR and skin prick testing in the
evaluation of asthma or rhinitis, readers are referred to
asthma and/or rhinitis guidelines. As testing for AHR
in clinical laboratories (as opposed to research
laboratories) is only validly performed in children aged
> 6 years, the recommendation is restricted to this age
group.
11. For children aged > 6 years and £ 14 years with
chronic cough and asthma clinically suspected, we
suggest that a test for airway hyperresponsiveness
(AHR) be considered (Grade 2C).
Areas for Further Research
To advance and improve the management of chronic
cough in children, suggested areas of research include
the following:
1. Undertake multicenter cohort studies in various
clinical settings (community and hospital) that assess
the outcomes of children with acute cough that then
progresses to chronic cough.
2. Undertake RCTs on the efﬁcacy of cough in various
clinical settings, particularly in primary care. When
doing so, we suggest that validated cough outcomes, a
priori deﬁnitions, and “period effect” considerations
be used.
3. Delineate the risk-beneﬁt ratio of using different
deﬁnitions of cough durations (eg, 4 weeks, 8 weeks,
3 months).
4. Determine if the use of cough algorithms, found to
improve clinical outcomes in settings outside of pri-
mary care, are beneﬁcial in primary care, with
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appropriate training given to primary care
practitioners.
5. Evaluate whether cough management or testing
algorithms should depend on the duration and/or
severity in children with chronic cough.
6. Determine the most appropriate age cutoff used for
pediatric vs adult chronic cough guidelines (eg, 12, 14,
18 years).
Conclusions
In the past decade, the availability of single-center and
multicenter studies from several countries has improved
the evidence base of the 2006 CHEST Cough Guidelines6
approach. The new recommendations formulated from
systematic reviews addressing ﬁve KQs were endorsed by
the CHEST Expert Cough Panel. Although there is high-
quality evidence for some of the new recommendations,
many questions remain, particularly in primary care for
which there is scarcity of data.
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